Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Jun;96(3):484–490. doi: 10.1111/j.1365-2249.1994.tb06055.x

Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients.

N Karimine 1, S Arinaga 1, H Inoue 1, S Nanbara 1, H Ueo 1, T Akiyoshi 1
PMCID: PMC1534563  PMID: 8004819

Abstract

Lymphokine-activated killer (LAK) cells generated by culture of peripheral blood mononuclear cells (PBMC), spleen cells (SPC) and regional lymph node cells (LNC) with IL-2 for 4 days were examined for their functional capabilities in 29 patients with gastric carcinoma. The cytotoxic activity of LAK cells induced from LNC was significantly lower than that from either PBMC or SPC, although there was no difference between PBMC or SPC. The induction of mRNA of interferon-gamma (IFN-gamma) or tumour necrosis factor-alpha (TNF-alpha) and the production of these cytokines in the non-adherent LAK cells from LNC were also significantly reduced compared with those from PBMC or SPC. Further, the LAK cells from LNC secreted significantly lower levels of these cytokines when stimulated with tumour target, Raji cells, although the production of these cytokines was markedly increased by stimulation with the targets in all three cell populations. Phenotypic analysis of each cell population revealed a decreased proportion of the cells mediating natural killer (NK) activity, including CD16+, CD56+, and CD57+ cells in LNC either before or after culture, although OKIa1+ and CD25+ cells were uniformly increased in all cell populations after culture. Changes in subpopulations of CD4+ and CD8+ cells in LNC were not apparently different from PBMC or SPC. These results indicated the differential reactivity of each lymphocyte population to IL-2 and the reduced LAK cell function of LNC compared with PBMC or SPC in patients with gastric carcinoma.

Full text

PDF
484

Images in this article

486Fig. 2
on p.486

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyoshi T., Koba F., Arinaga S., Tsuji H. Activated killer cell activity of spleen cells from patients with gastric carcinoma. J Clin Lab Immunol. 1987 Aug;23(4):197–201. [PubMed] [Google Scholar]
  2. Akiyoshi T., Koba F., Tsuji H. Activated killer cell activity in lymph nodes. J Clin Lab Immunol. 1987 Feb;22(2):91–95. [PubMed] [Google Scholar]
  3. Allavena P., Scala G., Djeu J. Y., Procopio A. D., Oppenheim J. J., Herberman R. B., Ortaldo J. R. Production of multiple cytokines by clones of human large granular lymphocytes. Cancer Immunol Immunother. 1985;19(2):121–126. doi: 10.1007/BF00199719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barth R. J., Jr, Mulé J. J., Spiess P. J., Rosenberg S. A. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med. 1991 Mar 1;173(3):647–658. doi: 10.1084/jem.173.3.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Belldegrun A., Kasid A., Uppenkamp M., Rosenberg S. A. Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid. Cancer Immunol Immunother. 1990;31(1):1–10. doi: 10.1007/BF01742489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Berd D., Mastrangelo M. J. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 1988 Mar 15;48(6):1671–1675. [PubMed] [Google Scholar]
  7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  8. Chong A. S., Aleksijevic A., Scuderi P., Hersh E. M., Grimes W. J. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets. Cancer Immunol Immunother. 1989;29(4):270–278. doi: 10.1007/BF00199215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chong A. S., Scuderi P., Grimes W. J., Hersh E. M. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. J Immunol. 1989 Mar 15;142(6):2133–2139. [PubMed] [Google Scholar]
  10. Chong A. S., Ybarrondo B., Grimes W. J., Hersh E. M., Scuderi P. Phenotypic analyses of lymphokine-activated killer cells that release interferon gamma and tumor necrosis factor alpha. Cancer Immunol Immunother. 1990;31(4):255–259. doi: 10.1007/BF01789178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cozzolino F., Torcia M., Carossino A. M., Giordani R., Selli C., Talini G., Reali E., Novelli A., Pistoia V., Ferrarini M. Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response. J Exp Med. 1987 Aug 1;166(2):303–318. doi: 10.1084/jem.166.2.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Damle N. K., Mohagheghpour N., Engleman E. G. Soluble antigen-primed inducer T cells activate antigen-specific suppressor T cells in the absence of antigen-pulsed accessory cells: phenotypic definition of suppressor-inducer and suppressor-effector cells. J Immunol. 1984 Feb;132(2):644–650. [PubMed] [Google Scholar]
  13. Dupere S., Obiri N., Lackey A., Emma D., Yannelli J., Orr D., Birch R., O'Connor T. E. Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro. J Biol Response Mod. 1990 Apr;9(2):140–148. [PubMed] [Google Scholar]
  14. Gemlo B. T., Palladino M. A., Jr, Jaffe H. S., Espevik T. P., Rayner A. A. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988 Oct 15;48(20):5864–5867. [PubMed] [Google Scholar]
  15. Grabstein K., Dower S., Gillis S., Urdal D., Larsen A. Expression of interleukin 2, interferon-gamma, and the IL 2 receptor by human peripheral blood lymphocytes. J Immunol. 1986 Jun 15;136(12):4503–4508. [PubMed] [Google Scholar]
  16. Gray P. W., Goeddel D. V. Structure of the human immune interferon gene. Nature. 1982 Aug 26;298(5877):859–863. doi: 10.1038/298859a0. [DOI] [PubMed] [Google Scholar]
  17. Hinuma S., Onda H., Naruo K., Ichimori Y., Koyama M., Tsukamoto K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun. 1982 Nov 30;109(2):363–369. doi: 10.1016/0006-291x(82)91729-6. [DOI] [PubMed] [Google Scholar]
  18. Itoh K., Shiiba K., Shimizu Y., Suzuki R., Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). J Immunol. 1985 May;134(5):3124–3129. [PubMed] [Google Scholar]
  19. Kasahara T., Hooks J. J., Dougherty S. F., Oppenheim J. J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol. 1983 Apr;130(4):1784–1789. [PubMed] [Google Scholar]
  20. Kasid A., Director E. P., Rosenberg S. A. Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol. 1989 Jul 15;143(2):736–739. [PubMed] [Google Scholar]
  21. Kovacs E. J., Beckner S. K., Longo D. L., Varesio L., Young H. A. Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2. Cancer Res. 1989 Feb 15;49(4):940–944. [PubMed] [Google Scholar]
  22. Landay A., Gartland G. L., Clement L. T. Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses. J Immunol. 1983 Dec;131(6):2757–2761. [PubMed] [Google Scholar]
  23. Nakamura H., Ishiguro K., Mori T. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Cancer. 1988 Dec 15;62(12):2489–2497. doi: 10.1002/1097-0142(19881215)62:12<2489::aid-cncr2820621207>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  24. Nedwin G. E., Svedersky L. P., Bringman T. S., Palladino M. A., Jr, Goeddel D. V. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol. 1985 Oct;135(4):2492–2497. [PubMed] [Google Scholar]
  25. Owen-Schaub L. B., Gutterman J. U., Grimm E. A. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 1988 Feb 15;48(4):788–792. [PubMed] [Google Scholar]
  26. Peters P. M., Ortaldo J. R., Shalaby M. R., Svedersky L. P., Nedwin G. E., Bringman T. S., Hass P. E., Aggarwal B. B., Herberman R. B., Goeddel D. V. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol. 1986 Oct 15;137(8):2592–2598. [PubMed] [Google Scholar]
  27. Pross H. F., Baines M. G., Rubin P., Shragge P., Patterson M. S. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981 Jan;1(1):51–63. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  28. Rivoltini L., Gambacorti-Passerini C., Squadrelli-Saraceno M., Grosso M. I., Cantù G., Molinari R., Orazi A., Parmiani G. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 1990 Sep 1;50(17):5551–5557. [PubMed] [Google Scholar]
  29. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  30. Rubbert A., Manger B., Lang N., Kalden J. R., Platzer E. Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer. 1991 Aug 19;49(1):25–31. doi: 10.1002/ijc.2910490106. [DOI] [PubMed] [Google Scholar]
  31. Schwartzentruber D. J., Topalian S. L., Mancini M., Rosenberg S. A. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol. 1991 May 15;146(10):3674–3681. [PubMed] [Google Scholar]
  32. Silvennoinen O., Vakkila J., Hurme M. Accessory cells, dendritic cells, or monocytes, are required for the lymphokine-activated killer cell induction from resting T cell but not from natural killer cell precursors. J Immunol. 1988 Aug 15;141(4):1404–1409. [PubMed] [Google Scholar]
  33. Steffen M., Ottmann O. G., Moore M. A. Simultaneous production of tumor necrosis factor-alpha and lymphotoxin by normal T cells after induction with IL-2 and anti-T3. J Immunol. 1988 Apr 15;140(8):2621–2624. [PubMed] [Google Scholar]
  34. Vitolo D., Vujanovic N. L., Rabinowich H., Schlesinger M., Herberman R. B., Whiteside T. L. Rapid Il-2-induced adherence of human natural killer cells. Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells. J Immunol. 1993 Aug 15;151(4):1926–1937. [PubMed] [Google Scholar]
  35. Voltarelli J. C., Rayner A. A., Garovoy M. R., Stites D. P. Human spleen and peripheral blood lymphocytes activated by interleukin-2 have similar phenotypic and functional characteristics. J Biol Response Mod. 1990 Feb;9(1):103–107. [PubMed] [Google Scholar]
  36. Williamson B. D., Carswell E. A., Rubin B. Y., Prendergast J. S., Old L. J. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5397–5401. doi: 10.1073/pnas.80.17.5397. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES